Clinical trial registry record

Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 20, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT06164587
Last registry update
July 20, 2026
Status
Completed
Phase
Phase 1, Phase 2
Sponsor
Inflammasome Therapeutics
Enrollment
30
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
30
Population
ALL · 50 Years to 99 Years
Duration
2024-04-18 to 2026-05-15
Intervention
K8
Comparator
Not reported
Outcomes measured
Adverse Events — Within the study period (of 26 weeks); Mean change in best-corrected visual acuity (BCVA) — At baseline visit, week 13 visit, and week 26 visit; Mean change in low-luminance best-corrected visual acuity (ll-BCVA) — At baseline visit, week 13 visit, and week 26 vis…; Change in size of geographic atrophy (GA) on fundus autofluorescence (FAF) — At baseline visit, week 13 visit, and week…; change in size of geographic atrophy (GA) on optical coherence tomography (OCT) — At baseline visit, week 13 visit, and…; change in size of geographic atrophy (GA) on fluorescein angiogram (FA) — At baseline visit, week 13 visit, and week 26…; Change in multifocal electroretinograms (mfERG) response — At baseline visit, week 13 visit, and week 26 visit; Change in microperimetry response — At baseline visit, week 13 visit, and week 26 visit; Change in reading speed — At baseline visit, week 13 visit, and week 26 visit; Discontinued subjects — This will be done at every scheduled visit and any unscheduled visit, as well as when reported…; Change in best corrected visual acuity (BCVA) over multiple time points — Day 2 visit, Week 4 visit, Week 13 visit, Wee…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: aging, age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON